Analyst consensus rating
Milestone Pharmaceuticals Analyst Rating: Strong Buy
MIST is rated Strong Buy by 7 analysts with a $5.86 target. As of 2026-08-24.
Direct answer
Milestone Pharmaceuticals's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.86.
Forecast evidence checked August 24, 2026.
Get free Milestone Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.04
- Average price target
- $5.86
- High price target
- $8.00
- Low price target
- $2.00
- Low target gap
- +92.3%
- Target upside
- +463.2%
- High target gap
- +669.2%
- Target range width
- 576.9%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Milestone Pharmaceuticals?
Milestone Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $5.86.
How far are Milestone Pharmaceuticals's low and high targets from the recorded price?
The low target implies +92.3%, while the high target implies +669.2%.
How many analysts are included in Milestone Pharmaceuticals's consensus?
The verified consensus includes 7 analysts.
How is Milestone Pharmaceuticals's target upside or downside calculated?
The average target of $5.86 is divided by the recorded price of $1.04, then one is subtracted to produce +463.2%. This does not guarantee a future return.
When was Milestone Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.